A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Clinical trial NCT05627856 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05627856
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-21
- Primary completion
- 2025-12-01
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.